Welcome to our dedicated page for Cellectis SEC filings (Ticker: CLLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Cellectis鈥檚 latest 10-K often means navigating hundreds of pages packed with gene-editing science, FDA trial protocols, and complex revenue-sharing notes. If you need to pinpoint when UCART clinical data could trigger milestone payments鈥攐r verify cash runway assumptions buried in footnotes鈥攜ou know the challenge of deciphering this biotech鈥檚 disclosures.
Stock Titan solves that problem. Our AI transforms every Cellectis quarterly earnings report 10-Q filing, Cellectis annual report 10-K simplified, and Cellectis 8-K material events explained into concise highlights you can scan in minutes. Want instant alerts on Cellectis insider trading Form 4 transactions? We stream Cellectis Form 4 insider transactions real-time so you can track executive stock moves before markets react. Each filing comes with plain-English summaries, keyword search across sections, and side-by-side comparisons to prior periods鈥攊deal for spotting shifts in R&D spend or partnership economics.
Whether you鈥檙e analyzing trial-stage burn rates, monitoring Cellectis proxy statement executive compensation, or seeking a quick Cellectis earnings report filing analysis ahead of a catalyst date, our platform keeps you current. Investors use these insights to:
- Monitor executive stock transactions Form 4
- Compare quarter-over-quarter trial expense trends
- Flag new risk factors in seconds, understanding Cellectis SEC documents with AI
Form 8-K Highlights: Hyperion DeFi, Inc. (formerly Eyenovia, Inc.) filed a current report covering two principal matters: (1) departure of its Chief Operating Officer and (2) a corporate name and ticker change.
Executive departure (Item 5.02): Effective July 1, 2025, COO Bren Kern鈥檚 employment terminated in connection with a previously announced reduction-in-force. Under a Separation and Release Agreement, he will receive 12 months of base salary and up to 12 months of continued health-care benefits, conditioned upon standard release and covenant provisions. The agreement is attached as Exhibit 10.1.
Name and ticker change (Item 5.03): A Certificate of Amendment filed June 30, 2025, changed the company鈥檚 legal name from Eyenovia, Inc. to Hyperion DeFi, Inc., effective 8:00 a.m. ET on July 1, 2025. Board approval under Delaware General Corporation Law 搂242 was sufficient; no stockholder vote was required. Common shares retain the same rights and CUSIP, but the Nasdaq ticker will convert from 鈥淓YEN鈥� to 鈥淗YPD鈥� beginning July 3, 2025.
Reg FD disclosure (Item 7.01): A press release regarding the rebrand and ticker change was furnished (Exhibit 99.1) and is not deemed 鈥渇iled鈥� for Exchange Act liability.
Exhibits:
- 3.1 鈥� Certificate of Amendment (Name Change)
- 10.1 鈥� Separation and Release Agreement (COO)
- 99.1 鈥� Press Release announcing changes
- 104 鈥� Inline XBRL cover page
The filing is primarily administrative; it signals a strategic rebranding without altering share structure, while simultaneously disclosing senior management turnover that may raise continuity concerns.
Credo Technology Group Holding Ltd (NASDAQ: CRDO) has received a Form 144 filing indicating a planned disposition of 80,000 common shares.
Key details are as follows:
- Filer/Account holder: Walden Technology Ventures II LP (address in Grand Cayman).
- Broker: Morgan Stanley Smith Barney LLC, Executive Financial Services, New York, NY.
- Class: Common stock.
- Approximate sale date: 24 Jun 2025, on the NASDAQ exchange.
- Aggregate market value of planned sale: US$7,261,816, implying an indicative price of about US$90.77 per share.
- Shares outstanding: 169,801,216, so the planned sale equals roughly 0.05 % of CRDO鈥檚 total shares.
The filing also discloses that the shares were originally acquired directly from the issuer on 8 Dec 2017 (58,770 shares) and 22 Dec 2020 (21,230 shares) for cash consideration.
Recent trading activity: Over the last three months Walden Technology Ventures II LP has already sold 404,297 CRDO shares in five transactions, generating cumulative gross proceeds of roughly US$31.5 million. The largest single sale was 171,473 shares on 16 Jun 2025.
Because Rule 144 notices are intent to sell filings, the shares may or may not ultimately be sold, and no pricing information beyond the aggregate value is provided. The proposed volume is small relative to CRDO鈥檚 float, suggesting limited direct market impact, but continuing distributions by a venture-capital holder may be noteworthy to investors monitoring insider supply dynamics.
Cellectis S.A. (Nasdaq: CLLS) filed a Form 6-K to disclose outcomes of its 26 June 2025 Combined General Meeting of Shareholders and subsequent Board re-composition. The filing formally incorporates the voting tally (Exhibit 99.1) and the accompanying press release (Exhibit 99.2) into several active U.S. shelf and equity compensation registration statements.
Board and Audit Committee changes: Shareholders elected Andr茅 Muller to the Board with immediate effect. Concurrently, the mandate of Axel-Sven Malkomes lapsed and the previously announced resignation of Pierre Bastid became effective. Following these departures, the Board re-constituted its Audit Committee, naming Mr. Muller as Chair alongside Donald Bergstrom and Rainer Boehm. The company states that all three members meet both Nasdaq Global Market and SEC Rule 10A-3 independence criteria, ensuring continued compliance with U.S. listing requirements.
No financial statements, operational updates, or transaction details were provided in this submission. The report is limited to corporate governance matters and does not indicate any anticipated impact on Cellectis鈥� financial performance or strategic direction.
FAQ
What is the current stock price of Cellectis (CLLS)?
What is the market cap of Cellectis (CLLS)?
What does Cellectis specialize in?
How does Cellectis differentiate from competitors?
What are Cellectis鈥檚 proprietary technologies?
What challenges does Cellectis face?
What is the significance of allogeneic CAR-T therapies?
What market does Cellectis target?
Who are Cellectis鈥檚 main competitors?
What stage of development is Cellectis in?
